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Summary We describe four children with Dravet syndrome treated with the
combination of valproic acid (VPA) and topiramate (TPM) who developed transient
liver toxicity. The time-interval between fever, administration of acetaminophen,
epileptic status and liver enzyme disturbances in our four cases suggests that
accumulation of toxic acetaminophen-metabolites is possibly responsible for liver
toxicity. If acetaminophen and its metabolites cause those liver problems in children
treated with the combination of VPA and TPM, the advice to use acetaminophen for
treating fever in children using this combination, should be changed. Only future
clinical observations and research can solve this clinical dilemma.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Dravet syndrome (severe myoclonic epilepsy in
infancy) is characterized by febrile and afebrile,
generalised and partial seizures that start in theAbbreviations: ALAT, alanine aminotransferase; APTT, acti-
vated partial thromboplastin time; ASAT, aspartate aminotrans-
ferase; CBZ, carbamazepine; INR, International normalised ratio;
IV, intravenous; PT, prothrombin time; TPM, topiramate; VPA,
valproic acid (valproate)
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doi:10.1016/j.seizure.2007.07.003first year of life. Later, myoclonic seizures, atypical
absences and developmental delay occur. Seizures
are often therapy-resistant to antiepileptic drugs.
Antiepileptic treatment with valproic acid (VPA),
clobazam and stiripentol or the combination of
VPA and topiramate (TPM) is often advised.
Acute hepatic injury is a possible complication of
many drugs. Acute VPA-induced liver toxicity is fatal
in the majority of patients.1 Especially in very young
children the risk is high; the risk of fatal liver failure
in children under 2 years of age receiving VPA as
polytherapy is 1:600. In children between 3 and 10
years using VPA polytherapy the risk is 1:8.300.2 The
relation between TPM and hepatotoxicity has been. Published by Elsevier Ltd. All rights reserved.
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both publications the adult patients used multiple
antiepileptic drugs including TPM. No reports on
hepatotoxicity in children or adults receiving TPM
monotherapy have been published till now. There is
evidence that ingestion of acetaminophen in ther-
apeutic dosages can cause an evident rise in alanine
aminotransferase (ALAT) in 31—44% of healthy, adult
volunteers.5
We describe four children with Dravet syndrome
who developed a serious rise of liver enzymes. All
were treated with the combination of VPA, TPM and
acetaminophen.Case report
Case No. 1, a 5-month-old boy from non-related
parents visited our outpatient clinic because of
generalised tonic—clonic seizures and partial sei-
zures with rhythmic twitches of the tongue and
facial musculature. EEG registration showed multi-
focal spikes and for this reason carbamazepine (CBZ)
was started. Metabolic screening revealed no ami-
noaciduria, no organic aciduria and normal serum
total, free, and acyl-carnitine concentrations. Cer-
ebrospinal fluid analysis and MRI scan showed no
abnormalities. Because of the fact that his seizure
frequency worsened and myoclonic seizures were
noted, CBZ was withdrawn and VPA was initiated at
the age of 8 months. Several episodes of epileptic
status occurred, triggered by febrile episodes.
He was admitted to Kempenhaeghe epilepsy cen-
tre for further analysis and treatment. At the age of
12 months, TPM was added to his medication and
gradually increased, because of ongoing seizures.
The diagnosis of Dravet syndrome was confirmed
when a c.2684T > G (p.Leu895Arg) mutation was
found in exon 15 of the SCN1A gene.
At the age of 15-month, he suffered from an
epileptic status triggered by influenza B infection.
The day before, he was given acetaminophen
240 mg q.i.d. (73 mg/kg/day) by his parents in order
to suppress his fever. A rise in liver enzymes was
noted, and L-carnitine 100 mg/kg/day was started
on the day of admission. His antiepileptic medica-
tion was continued in dosages equal to those before
admission and acetaminophen was stopped. ASAT
(2229 U/l) and ALAT (2022 U/l) levels peaked at day
1. Coagulation times were increased (APTT 20.9 s;
INR 2.1). Screening for Hepatitis virus A, B and C,
Epstein-Barr virus and Cytomegalovirus was nega-
tive. A spontaneous decrease of transaminases and
coagulation parameters to almost normal values was
noticed in the week after admission. On discharge,
L-carnitine was added to his regular medication.Three months later, he was admitted again to the
paediatric intensive care unit because of an epilep-
tic status triggered by fever (39.5 8C) of unknown
origin. Also this time, his parents had given him
acetaminophen. The rise of liver enzymes and coa-
gulation disturbance was even more severe now
(ASAT 7326 U/l; ALAT 5203 U/l; APTT 24.4 s; PT
32 s; INR 2.6). VPA concentration was 45 mg/L (nor-
mal range 40—100 mg/L). Transaminases gradually
normalised despite the continuation of VPA, TPM,
and L-carnitine. Also this time, screening for viral
hepatitis was negative.
The medical histories of Case No. 1 and the other
three children are summarised in Table 1. Antiepi-
leptic drug concentrations were only measured in
case 1 (second episode), 3 and 4. All parents used
acetaminophen according to the manufacturers
instructions. The dose used at home was not docu-
mented at admission in the other children. It is
important to note that case Nos. 1 and 3 developed
a rise in liver enzymes while receiving adequate L-
carnitine prophylaxis (advised dose: 100 mg/kg/
day6,7). In case No. 2, carnitine concentration was
measured on the day of admission. At that moment
she showed a serious rise in transaminases. Total,
free, and acyl-carnitine concentrations in plasma
were normal. In case Nos. 3 and 4 the rise of
transaminases was less impressive, however a sig-
nificant elevation of ammonia was noted. Because
of the serious rise in ammonia, a partial ornithine
transcarbamylase deficiency was ruled out in both
children.Discussion
In Dravet syndrome (severe myoclonic epilepsy in
infancy), seizures are often therapy-resistant. In a
randomized add-on study, the addition of stiripentol
to VPA and clobazam has been shown effective in
Dravet syndrome.8 The efficacy of TPM in Dravet
syndrome has been proven in an open label study9
and in a retrospective analysis, adding TPM to the
combination of VPA, clobazam, and stiripentol
seemed helpful.10 In recent literature discussing
the treatment of Dravet syndrome, the combination
of VPA and TPM is advised, together with strict acute
seizure treatment andprevention of hyperthermia.11
The molecular basis of Dravet syndrome is a
mutation of the SCN1A gene expressing a sodium
channel alpha subunit. This sodium channel is only
expressed in neuronal tissue, so a relation between
liver failure and the SCN1A gene mutation does not
seem obvious.
VPA-induced hepatic failure has been related to
carnitine deficiency. Chronic use of VPA leads to a
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Table 1 Patient overview
Patient Diagnosis Age at admission
Reason admission
Medication (plasma
concentration)
ALAT/ASAT
Ammonia
Change in medication Follow-up
1/M M. Dravet 1 year and 3 months VPA 31 mg/kg/day 2229/2022 U/l Day 0: start L-carnitine
100 mg/kg/day
ASAT 42 U/l; ALAT 150 U/l day 8
SCN1A + Epileptic status;
Influenza B infection
TPM 6 mg/kg/day Clobazam
1.4 mg/kg/day Acetaminophen
42 mmol/l Continuation of VPA,
TPM and clobazam
Discharged on day 18
1 year and 6 months
Epileptic status Fever,
unknown origin
VPA 26 mg/kg/day (45 mg/L)
TPM 3.9 mg/kg/day Clobazam
1.2 mg/kg/day L-carnitine
70 mg/kg/day Acetaminophen
7326/5203 U/
l 35 mmol/l
Continuation of VPA,
TPM, clobazam and
L-carnitine
ASAT 66 U/l; ALAT 40 U/l day 16
2/F M. Dravet 1 year and 3 months VPA 41 mg/kg/day 5898/3186 U/l VPA stop Normal plasma carnitine on day
of admission
SCN1A+ Epileptic status
Adenovirus infection
TPM 5.7 mg/kg/day Ethosuximide
29 mg/kg/day Clonazepam
0.14 mg/kg/day Acetaminophen
49 mmol/l Carnitine 100 mg/
kg/day
ASAT 63 U/l; ALAT 89 U/l day 15
3/F M. Dravet 1 year and 7 months VPA 51 mg/kg/day (78 mg/L) 280/340 U/l VPA stop Normalisation of liver enzymes
SCN1A+ Post-influenza
pneumonia
TPM 10 mg/kg/day (1.8 mg/L) 134 mmol/l Continuation of
L-carnitine
VPA reintroduced after several
months without problems
Lamotrigine 1.0 mg/kg/day
(8.2 mg/L)
Start lactulose
Clonazepam 0.1 mg/kg/day
L-carnitine 60 mg/kg/day
Acetaminophen
4/F M. Dravet 3 years and 1 month VPA 27 mg/kg/day (123 mg/L) 480/340 U/l VPA stop Normalisation of liver enzymes
SCN1A+ RS virus bronchiolitis TPM 8.4 mg/kg/day 212 mmol/l Start L-carnitine VPA restarted after 1 month
without problems
Clobazam 0.3 mg/kg/day Start lactulose
Acetaminophen
Acute hepatic injury in four children with Dravet syndrome 95secondary carnitine deficiency and carnitine con-
centrations are even lower in children receiving
polytherapy including VPA. Children and adolescents
treated with TPM monotherapy show normal con-
centrations of carnitine.12
VPA-induced liver toxicity in caused by several
co-occurring mechanisms. L-carnitine supplementa-
tion is often recommended in young children who
are receiving VPA, especially those younger than 2
years with a complex neurological disorder who are
receiving multiple antiepileptic drugs.6,13 The effi-
cacy of L-carnitine supplementation has never been
determined, but only one child developing VPA-
induced liver failure while receiving adequate L-
carnitine supplementation has been reported.14
In a retrospective analysis, it has been shown that
the survival in patients with severe VPA-induced
hepatotoxicity is significantly higher after treatment
with L-carnitine (48% versus 10% without L-carnitine
suppletion).1 IV treatment is associated with signifi-
cant better survival than enteral treatment.1Table 2 Review of literature on hepatotoxicity due to topira
therapy
Patient Age/sex Diagnosis Medication
Bjoro et al. 3 39 years/F Complex
partial
seizures
Carbamazepi
800 mg/day
TPM 300 mg/
day; c
Doan and
Clendenning4
21 years/F Bipolar
disorder
and obesity
VPA 1000 mg/
day
TPM 200 mg/
day
Longin et al. 16 1 year and
5 months/M
Lennox-
Gastaut
syndrome
VPA 50 mg/
kg/day
TPM 7 mg/
kg/day
Bumb et al. 17 51 years/F Symptomatic
epilepsy after
clipping of
aneurysm
VPA 3600
mg/day
TPM 250 mg/
day
f
a ASAT level is not mentioned in the manuscript.
b Information which medication was immediately stopped is not
c The woman described by Doan and Clendenning was on a regim
contraceptive. Simultaneous with the introduction of TPM, clonazep
d Ammonia concentration not mentioned by Bjoro et al. In the arti
expressed in mg/dL (1 mg/dL = 0.588 mmol/L).
e Both the articles by Bjoro et al., Doan and Clendenning and Bu
f The woman described by Bumb et al. also used citalopram, omTPM is frequently used in children. In a recent
large open-label study, no rise in liver enzymes was
observed in any of the 277 children (age: 12 months
and 16 years) treated with add-on TPM.15 No reports
on hepatotoxicity after the introduction of TPM
monotherapy have been published till now.
A causal relation between TPM and hepatotoxicity
has beenmentioned in two case-reports.3,4 However,
both adults used polypharmacy (Table 2). Longin
et al.16 reported a child and Bumb et al.17 reported
an adult, both treated with VPA/TPM polytherapy
who developed an elevation of liver enzymes
(Table 2). Both patients were on stable VPA dosage
while TPM was gradually increased. Those reports
provide anecdotal evidence that TPM increases the
risk of liver toxicity when added to VPA.
Liver enzymes normalised in case No. 1 in both
episodes although both VPA and TPM were contin-
ued. In case Nos. 3 and 4 TPM was continued and VPA
initially stopped but reintroduced in an equal dose
without problems. This probably implicates thatmate and valproic acid (or carbamazepine) combination
ASAT/ALAT
Ammonia
Change in
medication
Follow-up
ne a/10.000 U/l b Liver
transplantation
d e
1909/1044 U/l All medication
stopped
Liver enzymes
peaked at day 8
42 mmol/l e Reintroduction
VPA & quetiapine
without elevation
of liver enzymes
>400/>150 U/l VPA & TPM
stopped
Complete
recovery of
liver enzymes
61 mmol/ld Carnitine 100
mg/kg/day
262/464 U/l VPA stopped; e Somnolence
improved in
a few days
52 mmol/ld TPM continued Normal ASAT
& ALAT
Start
gabapentin
given in this letter.
en of VPA, benztropine, risperidone, clonazepam and an oral
am was stopped and flurazepam was added to the medication.
cles by Longin et al. and Bumb et al., ammonia concentration is
mb et al. do not mention L-carnitine supplementation.
eprazole, enoxaparin and lorazepam.
96 J. Nicolai et al.there have to be other mechanisms beside the
exposure to VPA and TPM. A potential mechanism
for liver damage especially in this group is the
rigorous treatment of fever with acetaminophen.
Searching Medline and PUBMED, we have not been
able to find any interaction between VPA and acet-
aminophen or TPM and acetaminophen. However,
the time-interval between fever, ingestion of acet-
aminophen, seizures and discovery of liver enzyme
disturbances in our four cases and normal carnitine
concentrations at admission in case No. 3, suggest
that accumulation of metabolites of acetamino-
phen, due to inhibition of cytochrome P450 enzymes
by VPA and TPM, is possibly responsible for hepato-
toxicity. Another mechanism could be reduced glur-
uronide conjugation of acetaminophen due to the
fact that this pathway is already used in VPA elim-
ination. A very interesting study found that stiripen-
tol is able to prevent hepatic necrosis after
acetaminophen overdose in rats.18 Stiripentol inhi-
bits the synthesis of N-acetyl-p-benzoquinone-
imine, a highly reactive metabolite.18 In clinical
practice, the combination of stiripentol, VPA, and
TPM seems safe; in a retrospective series of 24
children no liver problems were reported.10
Case No 1. received 73 mg/kg/day acetamino-
phen. It is advised that the daily dose should not
exceed 75 mg/kg.19 However, also the use of acet-
aminophen in normal dose can lead to an elevation
of transaminases. In a recent paper, 145 healthy
volunteers were treated in a placebo-controlled
study with 4 g of acetaminophen for 14 days. 31—
44% of acetaminophen-treated adults showed a
maximum ALAT concentration of more than 3 times
the upper limit of normal.5 This result implicates
that doctors need to be aware that ingestion of
acetaminophen in doses that are thought to be safe,
might lead to raised transaminases.20 If acetamino-
phen and its metabolites cause those liver problems
in children treated with the combination of VPA and
TPM, the advice to use acetaminophen for treating
fever in children using this combination, should be
changed. Only future observations or research can
solve this dilemma.
An important interaction between VPA and TPM in
the clinical presentation of hyperammonic encepha-
lopathy has been reported in several case reports.
The combination of VPA and TPM can give rise to a
deterioration of encephalopathy by two different
mechanisms. I; TPM inhibits the carbonic anhydrase
enzymeand this has been shown to increase ammonia
levels.21 In this situation, cessation of TPM results in a
decrease of ammonia and subsequent improvement
of symptoms despite continuation of VPA.21
II; The other mechanism results in deterioration
of symptoms of encephalopathy without a rise ofvenous ammonia concentrations. This is a result of
inhibition of the glutamine synthetase enzyme by
TPM. Glutamine synthetase is essential in the break-
down of ammonia and glutamate inside neurons, so
inhibition leads to an increase of intracellular
ammonia concentrations. In several patients
reported, consciousness improved significantly after
withdrawal of TPM, although venous ammonia levels
did not change.21,22Conclusion
We report four young children diagnosed with Dra-
vet syndrome that developed a rise in liver enzymes
(and a rise of ammonia in two children) after admis-
sion because of an epileptic status. All were treated
with VPA and TPM and with acetaminophen because
of fever the days before admission. It is important to
note that liver toxicity occurred in two children
while they had adequate L-carnitine supplementa-
tion. The clinical course of those four children
supposes that there may be other mechanisms
beside the exposure to TPM and VPA.
The time-interval between fever, acetaminophen,
epileptic status and liver enzyme disturbances in our
four cases suggests that accumulation of toxic acet-
aminophen-metabolites is possibly responsible for
the liver toxicity. Only future research and clinical
observations can solve this clinical problem.References
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